SION - Sionna Therapeutics, Inc.
About Sionna Therapeutics, Inc. (https://www.sionnatx.com)
Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-directed CFTR corrector that has completed Phase 1 trial; SION-451, which is nucleotide-binding domain 1 stabilizer in Phase 1 trial; and SION-719, which is nucleotide-binding domain 1 stabilizer in Phase 2a proof-of-concept trial. The company was formerly known as Sling Therapeutics, Inc. and changed its name to Sionna Therapeutics, Inc. in July 2021. Sionna Therapeutics, Inc. was incorporated in 2019 and is headquartered in Waltham, Massachusetts.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Michael Cloonan | President, Chief Executive Officer & Director | 1971 | $1,030,642 USD |
| Elena H. Ridloff | CFO & Chief Business Officer | 1980 | $771,602 USD |
| Charlotte McKee | Chief Medical Officer & Head of Research and Development | 1965 | $647,922 USD |
| Caroline Stark Beer | Chief Business Officer | 1979 | $268,113 USD |
| Andy Chu | Vice President of Information & Technology | – | – |
| Cecile Le Camus | VP & Head of Medical Affairs | – | – |
| Erica Iorio | VP of Finance & Controller | – | – |
| Greg Hurlbut | Co-Founder & Senior Vice President of Discovery Research | – | – |
| Jennifer Fitzpatrick | Chief Legal Officer & Head of Program Management | 1977 | – |
| Juliet Labadorf | Senior Director of Investor Relations & Corporate Development | – | – |
| Kenneth A. Lock | Chief Commercial Officer | 1974 | – |
| Mara Furlow | Senior Vice President of Global Regulatory Affairs & Quality | – | – |
| Mark Munson | Co-founder & Senior Vice President of Medicinal Chemistry | – | – |
| Mark Trone | Senior VP & Head of CMC | – | – |
| Meghan Bagshaw | Vice President & Chief of Staff to CMO | – | – |
| Sarah J. Spencer | Vice President of Corporate Communications | – | – |
| Vanya Sagar | Chief People Officer | 1976 | – |